BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 12-Month Low - Should You Sell?

Key Points

• BridgeBio Oncology Therapeutics hit a new 52-week low of $8.50 and was last trading at $8.70 (volume 6,285), notably below its 50-day moving average of $10.19.
• Analyst sentiment is mixed but leans positive: three Buy ratings versus one Sell, an average rating of "Moderate Buy" and an average price target of $26, with recent upgrades including HC Wainwright raising its target to $29.
• The company has a market capitalization of about $676.7M, a negative P/E (-5.57), a beta of 0.51, and roughly 54.9% of shares held by institutions.

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $8.50 and last traded at $8.70, with a volume of 6285 shares changing hands. The stock had previously closed at $8.91.

Analyst Upgrades and Downgrades

BBOT has been the topic of a number of research analyst reports. HC Wainwright boosted their target price on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a "buy" rating in a research report on Friday, March 6th. Raymond James Financial raised BridgeBio Oncology Therapeutics to a "moderate buy" rating in a research report on Friday, January 9th. Stifel Nicolaus initiated coverage on BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They issued a "buy" rating and a $23.00 target price for the company. Finally, Weiss Ratings initiated coverage on BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They issued a "sell (d+)" rating for the company. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $26.00.

BridgeBio Oncology Therapeutics Stock Performance

The firm has a market capitalization of $676.73 million, a P/E ratio of -5.57 and a beta of 0.51. The business's 50-day moving average is $10.19.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC acquired a new stake in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $63,000. Persistent Asset Partners Ltd acquired a new stake in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $107,000. Squarepoint Ops LLC acquired a new stake in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $144,000. Quadrature Capital Ltd acquired a new stake in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $162,000. Finally, BIT Capital GmbH acquired a new stake in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $313,000. Hedge funds and other institutional investors own 54.89% of the company's stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics NASDAQ: BBOT is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.